COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
2.720
-0.360 (-11.69%)
At close: Sep 3, 2025, 4:00 PM
2.590
-0.130 (-4.78%)
After-hours: Sep 3, 2025, 5:32 PM EDT
COSCIENS Biopharma Employees
COSCIENS Biopharma had 40 employees as of December 31, 2024. The number of employees increased by 28 or 233.33% compared to the previous year.
Employees
40
Change
28
Growth
233.33%
Revenue / Employee
$236,050
Profits / Employee
-$471,050
Market Cap
9.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 40 | 28 | 233.33% |
| Dec 31, 2020 | 12 | -44 | -78.57% |
| Dec 31, 2014 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CSCI News
- 20 days ago - COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update - GlobeNewsWire
- 2 months ago - COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders - GlobeNewsWire
- 3 months ago - COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - GlobeNewsWire
- 4 months ago - COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 months ago - COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 months ago - COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - GlobeNewsWire
- 6 months ago - COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - Newsfile Corp
- 6 months ago - COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - GlobeNewsWire